Annals of NeurologyGenetic & Genomic MedicinePeer-reviewed journal article
De novo missense variants in SLC32A1 cause a neurodevelopmental disorder with epilepsy due to impaired GABAergic neurotransmission
Konrad PlatzeriD, Heinrich StichtiD, Caleb P. BuppiD, Mythily GanapathiiD, Elaine Maria PereiraiD, Gwenaël Le GuyaderiD, Frédéric BilaniD, Lindsay B. HendersoniD, Johannes R. LemkeiD, Holger TaschenbergeriD, Nils BroseiD, Rami Abou JamraiD, Sonja M. WojcikiD
Abstract
We describe four patients with a neurodevelopmental disorder and de novo missense variants in SLC32A1, the gene that encodes the vesicular GABA transporter (VGAT). The main phenotype comprises moderate to severe intellectual disability, early onset epilepsy within the first 18 months of life and a choreatic, dystonic or dyskinetic movement disorder. In silico modeling and functional analyses in cultured neurons reveal that three of these variants, which are located in helices that line the putative GABA transport pathway, result in reduced quantal size, consistent with impaired filling of synaptic vesicles with GABA. The fourth variant, located in the VGAT N-terminus, does not affect quantal size, but increases presynaptic release probability, leading to more severe synaptic depression during high frequency stimulation. Thus, variants in VGAT can impair GABAergic neurotransmission via at least two mechanisms, by affecting synaptic vesicle filling and by altering synaptic short-term plasticity. This work establishes de novo missense variants in SLC32A1 as a novel cause for a neurodevelopmental disorder with epilepsy.
- Citations
- 26
- FWCI
- 2.44
- Field percentile
- top 11%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Haploinsufficiency underlies the neurodevelopmental consequences of SLC6A1/GAT-1 variants
Dina Buitrago Silva, Marena I. Trinidad, … Arthur Wüster·medRxiv·Mar 9, 2022
- 4 Phenylbutyrate Plus Gene augmentation: A dual therapy To Rescue of SLC6A1 Variant Associated Developmental And Epileptic Encephalopathy
Aiden James Delahanty, Kaitlin C. James, … 康静琼·bioRxiv·Jun 19, 2026
- High-throughput imaging of GABA fluorescence as a functional assay for variants in the neurodevelopmental gene, SLC6A1
Christopher Michael McGraw, Guoqi Zhang, … Annapurna Poduri·bioRxiv·Nov 6, 2025
- Pathogenic ultra-rare variants in SLC6A1, SLC6A11, GAD1 and GAD2 are new & recurrent GABAergic loci for GGE syndromes
Seo‐Kyung Chung, Kate V. Everett, … Mark I. Rees·medRxiv·Apr 1, 2025
- Human mutations in SLITRK3 implicated in GABAergic synapse development in mice
Stéphanie Efthymiou, Wenyan Han, … Henry Houlden·Frontiers in Molecular NeurosciencePeer-reviewed·Mar 1, 2024
- Heterozygous and homozygous variants in STX1A cause a neurodevelopmental disorder with or without epilepsy
Johannes Luppe, Heinrich Sticht, … Konrad Platzer·European Journal of Human GeneticsPeer-reviewed·Dec 23, 2022